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ABSTRACT
Objectives: Ciclopirox olamine has been employed as an antifungal agent. An oral route of administration of Ciclopiroxa olamine causes irritation and 
ulceration of GIT because of this it is used in the form of topical formulation. In this research work, antifungal nanogel formulated to reduce size of 
particle, improve in-vitro release and in-vivo release study.
Methods: Ciclopirox olamine nanogels were prepared using homogenization technique and incorporation of Carbopol 940 as a gelling agent in 
producing a smooth antifungal nanogel (F1-F6).
Results: Antigungal Nanogels (F1-F6) were subjected to Fourier transform infrared study and showed no interaction between the drug and excipients. 
The best formulation (F6) elicited the high in-vitro release of 83.42% at 8 h; zeta-potential and particle size, obtained values were -27 mV and 230 nm 
correspondingly. In-vitro release kinetic models were shown that formulation-F6 follows First-order kinetics and high regression coefficient value 
r2 0.9866. Scanning electron microscope image of the best formulation-F6 depicts that no breakage of nanogel. The differential scanning calorimetry 
(DSC) thermogram of ciclopirox olamine was found to be 140.09.7°C. The DSC thermogram of physical mixture of carbopol 940 and Euragit-S 100 was 
found to be 129°C and 218°C. DSC study of nanogel (F6) showed no interaction between drug and excipients. The best formulation-F6 was subjected 
to in-vivo study on mice which showed better effect in treating dermatitis.
Conclusion: It would be concluded that the best formulation-F6 which elicited better in-vitro drug release and enhanced dermatitis scoring.
Keywords: Ciclopirox-olamine, Eudragit-S100, Glycerol, Dermatitis, Carbopol-940, Cellophane membrane.
INTRODUCTION
The most common skin problem is fungal infection caused by 
Trichophyton rubrum and Trichophyton mentagrophytes which are 
present in the environment. Fungi live on indoor surfaces and an 
outdoor in soil, on human skin and become extra complex in diabetes 
patient. A fungal infection characterized by red rashes and repeatedly 
substantial itching. Physicians prescribe a variety of medicines which 
are liquid to semi-solid and solid dosage forms. Most treatments require 
long-term oral dose of 3–9 months. The long-term use of oral medicines 
would increase the chances of side effect. Therefore, it is better to focus 
on topical drug delivery to reduce the duration of treatment. Out of the 
treatments, the most commonly used is topical preparations [1].
Ring worm of the body
Ringworm is caused by fungus and not a warm. It occurs typically on 
the torso and limbs. Ringworm on other areas of the body can have 
different names such as athlete’s foot and jock itch. The main symptom 
of ringworm is a ring-shaped rash and slightly raised edges. The 
skin inside these circular rashes usually looks healthy. The rash can 
spread and its often itchy. Ringworm is common fungal infection and 
highly contagious. It can usually be treated with topical formulations. 
Cutaneous candidiasis is a skin infection caused by candida fungi. This 
type of fungi is naturally present on and inside our bodies. When it 
overgrows, an infection can happen. Candida skin infections occur in 
areas that that are warm, moist and poorly ventilated. Some examples 
that can be affected include under the breasts and in the folds of the 
buttocks, such as in diaper rash. Onychomycosis is a fungal infection 
of your nails. It can affect the finger nails or the toe nails, although 
infections of the toe nails are common.
New therapy of nanotechnology and an increased understanding of 
fungal infection have brought us closer to the goal of being safe and 
efficacious for the treatment of fungal skin diseases [4]. Nanotechnology 
has potential applications in the administration of healing agents and in 
analytic procedures. The nano-particulates drug delivery system offers 
plenty of advantages over conventional dosage forms for example reduced 
toxicity, enhanced bio-distribution and improved patient compliance.
The necessity for evolving topical novel drug delivery systems using 
nanotechnology is rising day by day. Nanogels are highly biocompatible, 
biodegradable, good transport characteristics, and good permeation 
capabilities. The pharmaceutical manufacturing companies are 
concentrating on the expansion of the innovative system to deliver 
drugs with the view to improve their efficacy.
Ciclopirox olamine which belongs to an anti-fungal category used 
to treat superficial mycoses. Therefore, in the current research work 
ciclopirox olamine was chosen as an ideal drug molecule for topical 
preparation. The aim of the research work was to formulate and 




Ciclopirox olamine procured from Yarrow chemicals Research Pvt. 
Ltd, Mumbai. Cabopol-940 received from SDFC Pvt. Ltd. Eudragit 
RS100 purchased from Yarrow chem. Pvt. Ltd. Tween-80, potassium 
di-hydrogen phosphate, and sodium hydroxide obtained from Sisco 
laboratories Pvt. Ltd. Glycerol ordered from HiMedia Lab Pvt. Ltd. All 
other raw materials used are pharmaceutical grade.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i10.42421. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
Research Article
128
Asian J Pharm Clin Res, Vol 14, Issue 10, 2021, 127-134
 Patil and Kontamwar
Methodology
Pre-formulation studies
Estimation of λmax of Ciclopirox olamine: The solution containing 
concentration of 10 µg/ml ciclopirox olamine was prepared and 
scanned over the wavelength 200–400 nm using Ultraviolet (UV)-
1700 spectrometer, Shimadzu Co., JPN to estimate the wavelength of 
maximum absorbance [1].
Estimation of melting point
A small amount of ciclopirox olamine was introduced into the 
capillary tube and the capillary tube was attached to the twig of 
thermometer. Thermometer was placed into Thiele’s tube containing 
liquid paraffin [2]. Side support of the Thiele’s tube was heated and 
the temperature was observed at which melting of drug begins and 
complete.
Determination of saturation solubility of ciclopirox olamine
The saturation solubility was conducted using four different solvents 
such as methanol, ethanol, water, and phosphate buffer pH 7.4. 
Increments of ciclopirox olamine were added to each solvent and 
sonicated for 30 min until it reaches saturation. The saturated solution 
was centrifuged for 5 min and the aliquots supernatant solution were 
taken and diluted to 10 ml with the same solvents and subjected to UV-
quantification using UV-1700 spectrometer, Shimadzu Co., JPN.
Compatibility studies
To check compatibility of ciclopirox olamine along with polymer using 
Fourier transform infrared (FT-IR) were performed [3].
Standard curve of ciclopirox olamine
Ciclopirox-olamine was exactly weighed and dissolved to get 
concentration as the primary solution. 1 ml of the primary solution 
was taken to 10 ml volumetric flask to get as secondary stock 
solution [5]. 0.2–1 ml was taken from secondary stock solution to 
10 ml volumetric flask and diluted using phosphate buffer pH 7.4 to get 
concentration 2–10 µg/ml and measured using UV-1700 spectrometer, 
Shimadzu Co. JPN.
Formulation of ciclopirox-olamine nanogel
Accurately weighed quantity of ciclopirox-olamine, Eudragit S-100 
and Tween-80 as stabilizer were dissolved in glycerol with stirring 
and aqueous phase prepared using Carbopol-940 dissolved in water 
with continuous stirring and heat [3,6]. The drug containing phase 
was sonicated on Ultra-sonicator (Make of the equipment-Wemsan). 
The drug phase was added drop by drop into an aqueous phase with 
continous stirring to get a uniform emulsion (o/w emulsion) which was 
converted into nano-droplets using homogenizer (Make-Remi-motors). 
Homogenization was continued for 1 h at 8000 rpm. Triethanolamine 
was added to form nanogel. Prepared Ciclopirox-olamine nanogels 
were subjected to various tests.
Evaluation of ciclopirox-olamine nanogel
Ciclopirox-olamine nanogels were evaluated for these parameters: 
Physical appearance, determination of pH, estimation of practical yield, 
determination of homogeneity, estimation of drug content uniformity, 
determination of spreadability, determination of viscosity, Statistical 
analysis of experimental data by ANOVA using Excel, In-vitro-drug 
release study, release kinetic study, Particle size analysis, estimation 
of Zeta potential, differential scanning colorimetry (DSC), Scanning 
electron microscopy (SEM), In-vitro release data further subjected to 
statistical analysis using One-way ANOVA by GraphPad Prism5, FT-IR 
studies and anti-fungal activity of nanogel.
Physical appearance
One of the important characteristic features of nanogel formulations 
is clarity of the formulation [2,7]. The prepared anti-fungal nanogels 
were evaluated for clarity by visual checking against a black and white 
texture.
Measurement of pH
The formulated antifungal nanogels were measured pH using digital pH 
meter and make of the equipment-Digisun Electronics services [3].
Determination of practical yield
Percentage of practical yield calculated using the following formula.
% yield = the experimental yield divided by theoretical yield 
multiplied by 100.
Determination of homogeneity
Homogeneity by visual examination done for all developed nanogel has 
remained to set in the beaker [3,8]. Nanogels were tested for physical 
properties and presence of any particle.
Estimation of drug content uniformity
The estimation of drug in nanogel was carried out by employing 1gm of 
nanogel mixed with 50 ml of phosphate buffer pH 7.4 and membrane 
filter was used to filter obtained mixture. From this mixture, 2ml of 
sample was pipette out and made up to 10 ml sample was analyzed for its 
absorbance spectrophotometrically at 222 nm [3,9]. The concentration 
of the ciclopirox-olamine in the test sample was estimated from the 
calibration curve.
Determination of Nangogel spreadability
A test sample of 1gm of nanogel was placed in the two glass slides and 
1 kg weight was placed on the slide for 10 min to obtain a consistent 
thickness and spreadability of a test sample [3]. The spreadability of the 
test sample nanogel was measured within minute by keeping two slides.
Statistical data analysis using excel-sheet
The spreadability experimental data was subjected to statistical 
analysis using One-way ANOVA.
Measurement of viscosity of anti-fungal nanogel
Nanogels viscosity was measured using Brookfield viscometer (Dv-E, 
Brookfield). In this method, the spindle number-4 was almost touched 
the surface of nanogel [5,11,12]. Brookfield viscometer dial readings 
were noted at different rpm and viscosity was measured.
In-vitro release study
The in-vitro release of drug was performed for nanogel formulations 
(F1-F6) and standard drug. Franz diffusion cell (Make-Orchid 
scientific) containing cellophane dialysis membrane was used. The 
donor compartment was loaded with 1gm of nanogel soaked in 
phosphate buffer pH 7.4 solutions at room temperature under slow 
magnetic stirring [1,14,15]. At regular time intervals, 1 ml of aliquot 
was withdrawn from receptor chamber through the sampling port 
and immediately replaced with fresh buffer solution of same volume. 
Aliquot was diluted and the amount of drug released was determined 
using UV- spectrophotometer at 222 nm.
In-vitro release kinetic study
According to the principle of pharmacokinetics, the drug release kinetic 
for dosage form can be represented by various equations followed by 
various kinetic models [6,16,18].
Measurement of particle size and zeta potential
The mean size and Zeta potential of the best nanogel formulation (F6) 
was measured by using Horiba sizer.
DSC
DSC studies of the best formulation (F6) were performed using 
equipment DSC 60; Shimadzu. DSC thermogram showed that a sharp 
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endothermic peak at 140.49°C which matches with the melting point 
of ciclopirox olamine indicating that the drug purity. From the DSC 
overlay thermogram of pure drug-ciclopirox olamine and Eudragit-S 
100, it could be stated that no interaction between drug and excipients. 
Moreover, it also depicts that drug did not form a complex with 
excipients.
EMSEM analysis was performed using Imina applying a beam of 
electrons (having high-energy) in the range of 10,000 electron volts and 
the magnification power 600× [5,19,20].
FT-IR study
FT-IR antifungal nanogels were performed to check the interaction 
between ciclopirox olamine and polymer [5]. The FT-IR spectrum of 
nanogel was carried out by FT-IR JASCO 460 Plus shows that there is no 
interaction between excipient/ciclopirox olamine.
Statistical data analysis using GraphPad Prism5
Statistical in-vitro data analysis was performed using GraphPad Prism5 
by One-way ANOVA [6,21].
In-vivo studies of antifungal nanogel
Material and Method: Animal species: Balb/c mice, Sex: Female, Age: 
Adult, Test sample: Ciclopirox Olamine, Dose: Quantity sufficient for the 
affected area, Inducing agent: Imiquimod (IMQ), dose 3.124 mg/animal, 
Route of administration: Topical, Duration: 1 week after the induction.
Treatment protocol: The IMQ was applied on the shaved back of the 
balb/c mice. 62.5 mg of nangogel or 3.124 mg of the active component 
was applied daily. The treatment was started from the 8th day onwards 
and continued for 1 week [5,22]. Both the formulations were applied on 
the affected area of the skin and allowed it to absorb into the skin. After 
1-week treatment, the scoring was observed to evaluate the dermatitis.
RESULTS AND DISCUSSION
Per-formulation studies
Standard curve of ciclopirox olamine
λmax of ciclopirox olamine in phosphate buffer pH 7.4 showed the 
maximum absorbance at 222 nm that is similar to the reported value. 
Ciclopirox olamine concentration in each sample was analyzed using 
UV- spectrophotometer at 222nm. The calibration curve of ciclopirox 
olamine was linear over a concentration range 2–10 µg/ml and 
regression value r2=0.997 (Figs. 6 and 7).
Determination of melting-point
The melting-point of ciclopirox olamine was found to be 143°C as 
reported in literature.
Saturation solubility studies
The saturation solubility of ciclopirox olamine was estimated in 
various solvents. Solubility of ciclopirox olamine in ethanol, water, and 










1 O-H 1644 or 1646 (cm−1) 1629.5 (cm−1)
2 C=O 1700 (cm−1) 1554.5( cm−1)
3 N-H 3400 (cm−1) 3214.7( cm−1)









1 N-H 3305.96 3340
2 O-H 1635.86 1635.86
3 C-N 1112.45 1100
4 C=O 1024.56 1000
Formulations Physical appearance pH % Yield Homogeneity Drug content Spread ability Viscosity (cps)
F1 Clear 6.5 72% Homogeneous 76% 6.9 cm 8561
F2 Clear 6.8 77% Homogeneous 75% 7.4 cm 8791
F3 Clear 6.6 80% Homogeneous 68% 7.3 cm 9857
F4 Clear 6.7 70% Homogeneous 71% 7.6 cm 9766
F5 Clear 6.2 79% Homogeneous 73% 6.3 cm 9453
F6 Clear 6.9 82% Homogeneous 80% 7.9 cm 9666
All values are expressed as mean, n=3 
Table 1: Reported and observed frequencies FT-IR functional 
group range of ciclopirox olamine
Table 2: Reported and observed FT-IR frequencies of ciclopirox 
olamine nanogel Formulation (F6)
Table 3: A various assessment parameters for ciclopirox olamine nanogel
Fig. 1: Fourier transform infrared spectrum of ciclopirox olamine
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Fig. 2: Fourier transform infrared spectrum of Eudragit- S-100
Fig. 3: Fourier transform infrared Spectrum of Carbopol-940
FT-IR analysis
Ciclopirox olamine pure drug, polymer Eudragit S-100 and physical 
mixture of ciclopirox olamine and Eudragit S 100 recorded using FT-IR 
spectroscopy.
The FT-IR spectrum of ciclopirox olamine ando excipients were 
recorded using FT-IR spectrophotometer and were compared with 
standard functional frequencies and excipient physical mixture 
showed characteristic peaks of the drug due to C-N, O-H and N-H, 
C=O appeared at their respective wave numbers 1112.45, 1635.86, 
3305.96, 1024.56 cm−1 ciclopirox olamine with no major shifts 
indicating compatibility of drug and excipients. FT-IR study was 
achieved and nearly showed same characteristic peaks of ciclopirox 
olamine indicating no interaction and would be depicted that 
ciclopirox olamine was completely compatible with Eudragit-S 100 
used in the best formulation F6 (Figs. 2 and 3).
Evaluation of ciclopirox olamine nanogel
Prepared anti-fungal nanogels were subjected to various evaluation 
parameters like appearance, % yield, pH, drug content, spreadability 
and viscosity. The spreadability of nanogel was found to be in range 
of 6.2–7.9 cm. Viscosity range of nanogel was found to be 8516–9666 
dyne s/cm.
Statistical analysis by one-way ANOVA using excel-sheet
Experimental data of antifungal nanogel was subjected to statistical 
analysis using One-way ANOVA.
Kinetic  
models
Slope (n) Rate constant Regression 
coefficient
Zero order 1.2867 +3.2515 0.9902
First order 4.9999 -1.1492 0.984
Korsmeyer-Peppas 0.5517 -0.4671 0.9864





F1 F2 F3 F4 F5 F6
1 6.9 12.8 19.7 12.8 24.2 27.4 26.0
2 14.6 18.0 28.0 19.7 36.0 36.0 38.2
3 23.3 23.1 38.2 23.7 41.4  41.4  42.8
4 35.5 28.0 41.1 38.0 48.2 47.4 51.1
5 46.6 34.8 48.2 45.4 53.4  56.8  60.2
6 56.1 41.7 50.2 47.4  56.5  60.8 70.2
7 69.8 47.7 52.8 50.2 59.4  66.8 76.5
8 71.2 52.2 53.7 55.7 63.71  73.0 83.4
Table 4: % cumulative release of formulation (F1-F6) and pure drug
Table 5: Kinetic values obtained from in-vitro release of 
anti-fungal nanogel formulation-F6
Fig. 4: Infrared spectrum of nanogel formulation (F6)
Fig. 5: Statistical analysis by one-way ANOVA using Excel sheet
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Fig. 6: In-vitro release profile of Ciclopirox olamine nanogel 
formulations F1- F6
In-vitro release profile of ciclopirox olamine nanogel
Release data obtained from in-vitro release of nanogel formulations F1 
to F6, pure drug-ciclopirox olamine using Phosphate buffer pH 7.4 is 
shown in table and figure.
In-vitro release studies at different ratios, ciclopirox olamine and 
Eudragit-S 100 performed at 8 h using Franz Diffusion Cell apparatus. 
The in-vitro release results of nanogels F1-F6 were compared with 
ciclopirox olamine. Nanogel of ciclopirox olamine Eudragit-S 100 
and prepared using homogenization method showed drug release 
in formulations such as F1, F2, F3, F4, F5 and F6 were 52.28%, 
53.71%, 55.71%, 63.71% 73.14% 83.42% respectively. Nangogel 
formulation-F6 elicited highest rate of drug release. In-vitro drug 
release profile of formulation-F6 was observed 83.42% release at 8 h 
(Fig. 6).
Zeta potential of nanogel formulation-F6 was found to be −27mV which 
indicated that particles prevent aggregation and hence stability of 
nanogel (F6) would be maintained. The mean particle size of nanogel 
nanogel formulation F6 was found to be 230 nm.
Release kinetics-models
In-vitro release data was exposed to different kinetic models like 
Zero-order release kinetics model, First-order release kinetics model, 
Higuchi-diffusion release kinetic model and Peppa’s kinetic model. 
The regression co-efficient (r) and ‘n’ values of all the kinetic models 
are shown in table for nanogel formulation F6. Plots are shown in 
figure.
The higher degree of the co-rrelation co-efficient determines the 
suitable kinetic model that follows drug release kinetics from the above 
table; it was found that zero-order kinetics showed highest correlation 
coefficient than other kinetic models (Figs. 8-11).
Finalized nanogel formulation (F6) elicited highest in-vitro drug 
release 83.42% at 8 h, particle size and Zeta potential observed 230nm 
and -27mV, respectively, in-vitro release kinetic models for nanogel 
formulation-F6 was shown that it follows First-order kinetics and high 
regression coefficient value r2=0.9866.
DSC analysis
Ciclopirox olamine and the best formulations were subjected to 
DSC studies to know the dispersion of drug in polymer Eudragit-S 
100. DSC study was performed using the instrument Perkin Elmer 
4000. The DSC thermogram of ciclopirox olamine shows a sharp 
endotherm at 140.09°C which is near to the actual melting point of 
ciclopirox olamine. The ciclopirox olamine nanogel showed sharp 
endothermic peak at 218.08°C which is almost near to actual melting 
point of Eudragit-S 100. DSC thermogram of excipients showed the 
peak 129.4°C and the combined peak of Eudragit-S 100 was showed 
at 218.8°C (Figs. 13 and 14).
SEM images of ciclopirox olamine nanogel shown in the figure. SEM 
photographs of ciclopirox olamine nanogel appeared as spherical shape 
(Fig. 15).
Group Animal No. Erythema Scaling Thickening
IMQ control 1 3 3 4
2 4 2 3
3 3 2 3
4 4 3 3
5 4 2 3
6 3 2 4
Mean  3.5 2.3 3.3





7 2 1 2
8 3 2 2
9 3 1 3
10 2 2 1
11 2 2 2
12 3 2 3
Mean  2.5 1.7 2.2




13 1 2 2
14 2 1 2
15 2 0 1
16 1 1 2
17 2 0 1
18 2 1 1
Mean  1.7 0.8 1.5
SEM  0.2 0.3 0.2
Table 6: Dermatitis severity scoring data
Fig. 7: Zeta potential and particle size
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Fig. 13: Differential scanning calorimetry thermogram of 
Eudragit-S 100
Fig. 8: Zero- order release-kinetic model
Fig. 9: First-order kinetic release model
Fig. 10: Korsmeyer Peppa’s kinetic model
Fig. 11: Higuchi kinetic model
Fig. 14: Differential scanning calorimetry thermogram of drug 
ciclopirox olamine with Eudragit S-100 carbopol 940
After the treatment period the dermatitis was scored based on 
erythema, scaling, and thickening were scored independently on a 
scale from 0 to 4. Whereas 0-none; 1-slight; 2-moderate; 3-marked, and 
4-very marked (Figs. 16-19).
SEM
SEM of the nanogel (F6) performed using an instrument IMINA 
under the magnification of 600× and energy range 10,000 
electron volts and it was observed that 250nm size of the nanogel 
formulation F6. SEM image shows that there is no breakage of nanogel 
(Fig. 15).
Fig. 12: Differential scanning calorimetry thermogram of 
ciclopirox olamine
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Fig. 15: Scanning electron microscopy of nanogel  
formulation (F6)
Fig. 17: Dermatitis characterized by scaling and erythema scoring
Fig. 16: Grouped data by Graphpad prism using one-way ANOVA
Fig. 19: In-vivo study-dermatitis model mice in Imiquimod (IMQ), 
reference and test sample (Nanogel formulation-F6)
Fig. 18: Thickening dermatitis graph of antifungal nanogel-F6
Statistical analysis using GraphPad Prism5
Statistical analysis of in-vitro release of nanaogels (Pure Drug as PD and 
nanogels F1-F6) was performed by GraphPad Prism5 using One-way 
ANOVA by Dunniet.
In-vivo study of antifungal nanogel (F6)
Severity scoring of dermatitis
After the treatment period, the dermatitis was scored based on 
erythema, scaling and thickening were scored independently on a scale 
from 0 to 4, Whereas 0 value indicates-none; 1- slight; 2-moderate; 
3-marked and 4-very marked (Figs. 16-19).
CONCLUSION
Ciclopirox olamine nanogel was formulated using homogenization 
technique. The release profiles of prepared naongels exhibited an 
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inflection point which indicated nanogel formation on diffusion 
membrane in donor compartment of the diffusion cell. During nanogel 
formation, formulation got converted into the gel phase and drug release 
became slow. The result showed that effectively formulated stable 
antifungal nanogel encompassing ciclopirox olamine which would 
release drug for an extended period of time. Nangogel (F6) showed 
better local absorption with low systemic absorption of potentially toxic 
antifungal drug has verified to be promising approach for the treatment 
of actio mycosis. However, ciclopirox olamine test sample was found to 
be more potent than the marketed formulation because the dermatitis 
score was less in the test sample than the marketed formulation.
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